Therese Bredholt Onyangos bilde

Therese Bredholt Onyango

  • E-postTherese.Bredholt@uib.no
  • Telefon+47 55 58 63 37
  • Besøksadresse
    Laboratoriebygget, 5. etg.
    Haukeland University Hospital
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). Symptom burden and immune dynamics 6 to 18 months following mild SARS-CoV-2 infection -a case-control study. Clinical Infectious Diseases.
  • Vis forfatter(e) (2022). Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLOS ONE. 16 sider.
  • Vis forfatter(e) (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
  • Vis forfatter(e) (2020). A comparison of p53 isoform profiles and apoptosis induced by camptothecin or a herbal khat extract (Catha edulis (vahl) forssk. ex endl.) in leukemic cell lines: Exploring cellular responses in therapy development. Cancers. 1-14.
  • Vis forfatter(e) (2017). Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.
  • Vis forfatter(e) (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Vis forfatter(e) (2014). Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Vis forfatter(e) (2013). OK-432-stimulated chemokine secretion from human monocytes depends om MEK1/2, and involves p38 MAPK and NF-kB phosphorylation, in vitro. APMIS - Journal of Pathologiy, Microbiology and Immunology. 299-310.
  • Vis forfatter(e) (2013). Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 13 sider.
  • Vis forfatter(e) (2009). Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. Toxicology. 108-116.
  • Vis forfatter(e) (2009). Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer.
  • Vis forfatter(e) (2008). Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences. 23-30.
  • Vis forfatter(e) (2004). Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells. British Journal of Cancer. 1726-1726.
  • Vis forfatter(e) (2004). Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. Scandinavian Journal of Immunology. 189-198.
Vitenskapelig foredrag
  • Vis forfatter(e) (2006). Characterisation of Khat Induced Cell Death in Oral Fibroblasts.
  • Vis forfatter(e) (2005). Molecular mechanisms of apoptosis induced by khat extract and its alkaloids cathinone and cathine in acute myeloid leukemia.
  • Vis forfatter(e) (2005). Mechanisms of apoptosis induction by khat alkaloids in leukaemia cells.
  • Vis forfatter(e) (2005). Khat- and cathionine-induced apoptosis is modulated by Bcl-2 protein expression.
  • Vis forfatter(e) (2010). Delineating cellular and molecular mechanisms of toxicity of an extract of khat (Catha edulis Forsk.) in leukemia and normal peripheral blood cells.
  • Vis forfatter(e) (2011). MAPK ERK, p38, and JNK-Dependent Chemokine Secretion Following OK-432 Stimulation of Human Monocytes In Vitro. Scandinavian Journal of Immunology. 363-363.
  • Vis forfatter(e) (2006). Effects of khat (Catha edulis) on normal human oral cells. Journal of Oral Pathology & Medicine. 443-443.
  • Vis forfatter(e) (2005). The role of Bcl-2 in apoptosis induced by khat (Catha edulis) in acute myeloid leukemia cell lines. Blood. 195b-195b.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2007). Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. Current Pharmaceutical Biotechnology. 373-381.

Se fullstendig oversikt over publikasjoner i CRIStin.